This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US
September 23-26, 2024
Hynes Convention CenterBoston, MA

Preliminary Conference Agenda

Enabling Greater Success of Cell Therapy Commercialization

Hari Kamaraju, MS, MBA, Senior Scientist, Janssen Research & Development.

Advances in CAR T Cell Manufacturing

Isabelle Riviere, Ph.D., Director, Michael G. Harris Cell Therapy and Cell Engineering Facility, Molecular Pharmacology, Memorial Sloan Kettering Cancer Center

Process Development and Optimization in 3D Packed Bed Bioreactor Systems for Ensuring Successful Launch into Marketing Scale Manufacturing

Lior Raviv, Vice President of Development, Pluristem Therapeutics

Aseptic Processing Strategy for Cell Based Product Manufacturing

Julie Zhu, Ph.D., Associate Director, Janssen Pharmaceuticals

The Development of Animal-Component-Free, Chemically-De ned Culture Media for Immune Cells

Jessie Ni, Ph.D., Chief Scientific Officer, Irvine Scientific

Preliminary Workshop Agenda

Cell Based Immunotherapies: One Day Course

David Brindley, DPhil, MEng, FRSA Managing Partner, Biolacuna & Senior Research Fellow, Nuf eld Department of Paediatrics, University of Oxford, United Kingdom

Pre-Conference Symposia

Monday, September 25, 2017

  • Continuous Processing
  • Vaccine Development and Production: Novel Technologies and Strategies
  • Biosimilar Development and Production
  • Modern CMC Regulatory Strategies and Insights
  • Advanced Control Strategies in Bioprocessing and Biomanufacturing: Disruptive Technologies and Emerging Platforms for Biologics Facilities of the Future
  •  Cell-Based Immunotherapies